Axcella Health was a clinical-stage biotechnology company focused on developing endogenous metabolic modulator (EMM) compositions and designed amino acid compositions (DAAC) to treat complex diseases including metabolic, muscle, and neurological conditions. The company's lead program, AXA1125, was in development for Long COVID fatigue. Founded by Flagship Pioneering in 2011 and taken public in May 2019, the company was liquidated and dissolved in December 2023 after failing to meet primary endpoints in clinical trials.
Axcella is publicly traded
IPO'd on May 9, 2019
This company is no longer available on our private secondary market. Shares can be traded publicly under AXLA.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2011
Total Funding
$140.5M
3 rounds
Total raised $140.5M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series E
Date
November 2018
Amount
$59M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 2018 | Series E | $59M | — | Not disclosed |
| 2016 | Series D | $42.5M | — | Nestlé Health Science |
| 2015 | Series C | $39M | — | Fidelity Management and Research |
Bill Hinshaw
President and Chief Executive Officer
Yes, Axcella is publicly traded under the ticker symbol AXLA on the NASDAQ. The company went public in May 9, 2019.
Axcella trades under the ticker symbol AXLA on the NASDAQ. It began trading in May 9, 2019.
Axcella (AXLA on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker AXLA to place an order.
Axcella went public in May 9, 2019 via ipo. Axcella Health went public on NASDAQ under ticker AXLA on May 9, 2019, raising $71.4M in gross proceeds. The company was delisted on December 29, 2023, following stockholder approval of liquidation and dissolution on December 4, 2023. The company's lead program, AXA1125 for Long COVID fatigue, failed to meet its primary endpoint in a Phase IIa study in August 2023, leading to the decision to liquidate. Assets were transferred through an assignment for the benefit of creditors.
Axcella raised $140.5M across 3 disclosed funding rounds prior to its public listing.
Axcella is headquartered in Cambridge, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.